首页> 外文期刊>Expert opinion on drug delivery >Nano-based rescue of dysfunctional autophagy in chronic obstructive lung diseases
【24h】

Nano-based rescue of dysfunctional autophagy in chronic obstructive lung diseases

机译:慢性阻塞性肺病中的纳米功能障碍自噬拯救

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Delta F508-CFTR (cystic fibrosis transmembrane conductance regulator) is a common CF-mutation that is known to induce oxidative-inflammatory stress through activation of reactive oxygen species (ROS), which induces autophagy-impairment resulting in accumulation of CFTR in aggresome-bodies. Cysteamine, the reduced form of cystamine, is a FDA-approved drug that has anti-oxidant, anti-bacterial, and mucolytic properties. This drug has been shown in a recent clinical trial to decrease lung inflammation and improve lung function in CF patients by potentially restoring autophagy and allowing CFTR to be trafficked to the cell membrane.
机译:简介:Delta F508-CFTR(囊性纤维化跨膜电导调节剂)是一种常见的CF-突变,已知通过活化氧物种(ROS)激活氧化 - 炎症胁迫,这诱导了胃肠中的CFTR累积导致CFTR的累积 -身体。 半胱胺,减少的胱胺形式,是一种具有抗氧化剂,抗细菌和粘液裂解性的FDA批准的药物。 该药物已在最近的临床试验中显示,以降低肺炎,通过潜在恢复自噬降低CF患者的肺功能,并允许CFTR被贩运到细胞膜。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号